Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
Ocugen's lead programs are ophthalmic gene therapies targeting eye diseases (RP, Stargardt, GA).
|
$516.90M |
$1.79
+1.41%
|
|
Company focuses on oncology therapeutics leveraging protein engineering platforms.
|
$516.07M |
$35.38
-0.76%
|
|
ARCT-032 and ARCT-810 are mRNA-based therapies (gene therapy approach) targeting CF and OTC deficiency.
|
$513.94M |
$18.95
-5.11%
|
|
MGPI's Distilling Solutions segment operates as a contract manufacturer for distillates and aging, i.e., contract manufacturing services.
|
$507.12M |
$23.84
-2.65%
|
|
Rigel commercializes oral small-molecule therapeutics, including SYK, IDH1, and RET inhibitors, making this its core product category.
|
$503.65M |
$28.18
-0.77%
|
|
The company markets living cell therapies (Apligraf, Dermagraft) which are aligned with the cell therapy biotech category.
|
$502.34M |
$3.96
-2.46%
|
|
Esperion directly manufactures and sells oral small-molecule therapeutics (NEXLETOL and NEXLIZET).
|
$501.44M |
$2.53
+2.85%
|
|
Sengenics antibody profiling integration supports an antibody discovery capability within LAB's SomaScan service ecosystem.
|
$497.57M |
$1.31
-5.07%
|
|
Fulcrum's lead asset pociredir is an oral small molecule therapeutic, the core product category the company develops and would commercialize.
|
$485.27M |
$8.99
-7.37%
|
|
Emergent directly develops and commercializes vaccines (BioThrax, ACAM2000) as core Medical Countermeasure products.
|
$483.62M |
$8.91
+0.45%
|
|
Verastem focuses on oncology therapeutics, with AVMAPKI FAKZYNJA CO-PACK as its lead product in cancer.
|
$470.91M |
$8.57
-7.45%
|
|
The company markets an Antibody Discovery Platform that enables de novo antibody design and high-throughput validation, aligning with its manufacturing/design capabilities.
|
$469.42M |
$3.68
-8.46%
|
|
Astria's assets (navenibart and STAR-0310) are immunology therapeutics (antibody-based) addressing immune-mediated diseases (HAE and Atopic Dermatitis).
|
$468.97M |
$8.31
-4.04%
|
|
LY T-200 is a first-in-class monoclonal antibody for oncology, a core PureTech asset (Gallop Oncology) in the pipeline.
|
$464.27M |
$18.00
|
|
Solid is a gene therapy company developing multi-program viral-vector therapies (e.g., SGT-3.00 for DMD, SGT-212 for FA, SGT-501 for CPVT).
|
$461.99M |
$5.96
-7.31%
|
|
RPT904 is a monoclonal antibody targeting IgE, classifying as Monoclonal Antibody Therapeutics.
|
$443.00M |
$26.79
-10.52%
|
|
Core product is autologous cell therapy (obe-cel CAR-T) categorized under cell therapy.
|
$441.79M |
$1.66
-6.21%
|
|
Cullinan Therapeutics is a clinical-stage biotech focused on oncology, with assets including bispecific T-cell engagers and a targeted EGFR inhibitor, directly aligning with Biotech - Oncology.
|
$436.71M |
$7.40
+4.23%
|
|
Neurogene is a clinical-stage biotechnology company that directly develops gene therapies (NGN-401) for neurological diseases, i.e., a gene therapy business line.
|
$430.86M |
$30.21
-4.28%
|
|
Lead asset detalimogene voraplasmid is a gene therapy delivered using a non-viral DDX platform, aligning with Biotech - Gene Therapy.
|
$428.77M |
$8.39
-5.20%
|
|
FDMT's core business is precision gene therapy developed on its Therapeutic Vector Evolution platform, with lead assets like 4D-150 and 4D-710.
|
$412.29M |
$8.90
-7.29%
|
|
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), a core direct product the company sells.
|
$404.65M |
$4.36
+6.86%
|
|
Oligonucleotide Therapeutics: Korro Bio uses an oligonucleotide-based approach (OPERA) for RNA editing to therapeutically modify RNA.
|
$403.51M |
$42.97
-8.18%
|
|
Kamada maintains a biosimilar portfolio in Israel with planned launches, representing a direct revenue stream.
|
$390.86M |
$6.80
-2.72%
|
|
Core oncology-focused therapeutics with DANYELZA (anti-GD2).
|
$389.89M |
$8.61
|
|
Direct product category: bispecific antibody therapeutics developed for immuno-oncology.
|
$388.95M |
$4.77
-1.65%
|
|
iTeos Therapeutics is an oncology-focused biotech developing cancer immunotherapies, including anti-TIGIT antibodies and other immuno-oncology assets.
|
$388.48M |
$10.15
|
|
Lineage's lead programs OpRegen, OPC1, and ReSonance ANP1 are allogeneic cell therapies, making Biotech - Cell Therapy the core direct product focus.
|
$385.92M |
$1.69
-1.74%
|
|
Company's lead assets and platform focus on RNA interference–based therapeutics (ddRNAi), i.e., RNAi Therapeutics.
|
$381.96M |
$14.92
+5.89%
|
|
Lead program iluzanebart is a monoclonal antibody therapeutic targeting TREM2.
|
$375.71M |
$8.05
|
|
VASCEPA/icosapent ethyl is a cardiovascular drug indicated for reduction of major adverse cardiovascular events; core product in Amarin's portfolio.
|
$374.93M |
$18.23
-5.35%
|
|
Delcath markets a drug delivery platform (HEPZATO KIT) for liver-directed chemotherapy, fitting the 'Drug Delivery Platforms' investable theme.
|
$374.21M |
$10.74
-0.78%
|
|
Core business: development and commercialization of radiopharmaceuticals for diagnostic imaging and targeted alpha therapies.
|
$360.75M |
$4.86
+15.71%
|
|
NWBO's DCVax platform products are autologous dendritic cell therapies, i.e., a cell therapy business line.
|
$358.65M |
$0.25
+2.66%
|
|
AC Immune develops monoclonal antibodies via SupraAntigen; its pipeline includes antibody-based immunotherapies, fitting Monoclonal Antibody Therapeutics.
|
$354.43M |
$3.55
+0.28%
|
|
Lead candidate ARD-101 is an oral small-molecule therapeutic targeting TAS2R gut receptors to induce satiety, directly aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$352.78M |
$16.26
-1.99%
|
|
Replimune is a cancer-focused biotechnology company developing oncolytic immunotherapies, aligning with Biotech - Oncology.
|
$352.29M |
$4.67
+2.30%
|
|
Rocket’s core platform is viral-vector gene therapies (in vivo AAV and ex vivo LV) delivering genetic material to patients.
|
$351.23M |
$3.27
+0.46%
|
|
Company targets inherited nucleotide repeat expansion diseases (FA, FECD, DM1, HD), a class of rare genetic diseases, which fits the Biotech - Rare Diseases investment theme.
|
$346.86M |
$6.11
-4.08%
|
|
Tenaya is developing gene therapies (TN-201, TN-401) for cardiovascular genetic diseases using viral vectors, which directly maps to Biotech - Gene Therapy.
|
$341.60M |
$2.10
-5.19%
|
|
ANX005 (tanruprubart) is a monoclonal antibody therapeutic targeting C1q.
|
$340.11M |
$3.10
-4.91%
|
|
TOI plans to deploy Radiopharmaceutical Therapy (radioligand therapy) as part of its oncology care offering, representing a distinct therapeutic modality and revenue stream.
|
$338.20M |
$3.79
-4.05%
|
|
Direct ophthalmic drug development with reproxalap for dry eye and ADX2191 intravitreal therapy for retinal conditions.
|
$330.02M |
$5.51
-4.67%
|
|
Capricor's lead asset, deramiocel, is a cell-based therapy developed from cardiosphere-derived cells aimed at treating DMD cardiomyopathy.
|
$324.07M |
$7.09
-6.96%
|
|
Lead asset pemvidutide positions Altimmune as a pharmaceutical/biotech developer focused on metabolic and liver disease therapies, a core business area.
|
$317.94M |
$3.92
-2.73%
|
|
Fanapt and bipolar I disorder expansion, plus a broader psychiatry-focused pipeline, align with Neuropsychiatric Drug Development.
|
$312.94M |
$5.31
-3.80%
|
|
Direct focus on developing therapies for rare genetic diseases (OI, AATD-LD) classifies Mereo under Biotech - Rare Diseases.
|
$311.64M |
$1.96
-6.67%
|
|
Editas Medicine is a biotech company developing in vivo gene-editing therapeutics (gene therapy) using its Cas12a-based platform.
|
$311.41M |
$3.72
-11.85%
|
|
Candel Therapeutics focuses on oncology using viral immunotherapies (CAN-2409, CAN-3110).
|
$310.14M |
$6.19
-6.07%
|
|
Core business focus on neuropsychiatric drug development, including navacaprant and NMRA-511 with a CNS/neurodegenerative pipeline.
|
$305.70M |
$1.89
-3.08%
|
|
Alector's ABC Platform is a proprietary platform for delivering diverse therapeutics across the blood-brain barrier, enabling brain-targeted delivery of antibodies and other cargo.
|
$301.98M |
$3.02
-5.48%
|
|
TX45 is a peptide-based therapeutic protein (Fc-relaxin fusion) targeting GPCR RXFP1.
|
$299.13M |
$16.02
-6.10%
|
|
Lead programs target oncology indications (cancer) via galectin-3 inhibition; core business focus.
|
$298.74M |
$4.72
-1.05%
|
|
Aura's lead program bel-sar is a cancer therapy targeting solid tumors, representing its core oncology business.
|
$297.59M |
$5.92
-2.95%
|
|
CNS/neuropsychiatric drug development focus including RRMS and MDD positions Contineum in the Neuropsychiatric Drug Development theme.
|
$293.64M |
$11.16
-1.63%
|
|
Immutep develops oncology immunotherapies (eftilagimod alfa) for cancer, aligning with Biotech - Oncology.
|
$292.57M |
$2.01
-2.90%
|
|
Direct cell therapy product category; off-the-shelf allogeneic CAR-T (UCART22/UCART20x22).
|
$291.26M |
$4.04
-3.81%
|
|
Viaskin Peanut patch is an immunotherapy platform targeting immune modulation in pediatric peanut allergy, aligning with Immunology Therapeutics.
|
$289.50M |
$15.00
-3.29%
|
|
KYV-101 is an autologous CD19 CAR T-cell therapy, the core product line for Kyverna.
|
$286.54M |
$6.63
-5.69%
|
|
Bright Minds Biosciences develops CNS/psychiatric therapeutics (5-HT receptor agonists) and is advancing BMB-101 in Phase 2, aligning with Neuropsychiatric Drug Development.
|
$282.52M |
$63.29
+2.58%
|
|
Lead oncology candidate MIE-101 immunotherapy platform directly positions the company in Biotech - Oncology.
|
$280.13M |
$0.70
|
|
Larimar focuses on a rare-disease target (Friedreich's ataxia) and develops niche therapeutic solutions, fitting Biotech - Rare Diseases.
|
$279.16M |
$4.36
-3.75%
|
|
Core product category is gene therapies using TRACER capsids and payloads (e.g., VY7523, VY1706, APOE, SOD1) enabling IV-delivered CNS gene therapy.
|
$276.68M |
$5.00
-3.29%
|
|
ABEO's lead asset is a gene therapy product targeting recessive dystrophic epidermolysis bullosa (RDEB).
|
$273.18M |
$5.34
-1.11%
|
|
PEDMARK is an FDA-approved oncology therapy addressing cisplatin-induced ototoxicity in pediatric patients, making Biotech - Oncology the core product offering.
|
$272.87M |
$9.82
-0.56%
|
|
Allogene's primary products are off-the-shelf allogeneic CAR T cell therapies (cell therapy).
|
$269.04M |
$1.23
-14.58%
|
|
Atea's lead assets bemnifosbuvir and ruzasvir are oral small-molecule antivirals targeting HCV.
|
$268.72M |
$3.14
+0.32%
|
|
CX-2051 is an EpCAM-directed PROBODY ADC, directly making Antibody-Drug Conjugates.
|
$266.05M |
$3.30
+1.23%
|
|
Lyell's core direct product is LYL314, a CAR-T cell therapy (cell therapy) targeting cancer, which directly aligns with Biotech - Cell Therapy.
|
$262.11M |
$17.75
+11.99%
|
|
Inozyme's lead program INZ-701 targets ENPP1 Deficiency, a rare genetic disorder, placing the company squarely in Biotech - Rare Diseases.
|
$256.96M |
$4.00
|
|
Apraglutide targets a rare-disease indication (SBS-IF) and is part of Ironwood's strategic pivot into Rare Diseases.
|
$256.48M |
$1.58
-15.24%
|
|
Puma Biotechnology directly develops oncology therapies and commercializes NERLYNX, a cancer drug, aligning with Biotech - Oncology.
|
$254.15M |
$5.12
-2.29%
|
|
Directly produces and develops oral small molecule therapeutics (NLRP3 inhibitors) for autoimmune, inflammatory, and neuroinflammatory diseases.
|
$253.33M |
$3.56
-7.77%
|
|
Solésence provides contract development and manufacturing services for beauty and personal care brands (CDMO).
|
$249.57M |
$3.56
-1.11%
|
|
Sagimet Biosciences designs and develops FASN inhibitors (denifanstat, TVB-3567) for metabolic diseases and oncology, aligning with Biotech - Oncology.
|
$247.10M |
$7.67
-10.96%
|
|
Narsoplimab and OMS1029/zaltenibart are monoclonal antibody therapeutics.
|
$245.50M |
$4.19
-8.71%
|
|
Zura Bio's lead and pipeline assets are immunology-focused antibodies (e.g., tibulizumab targeting IL-17A and BAFF), placing the company squarely in Immunology Therapeutics.
|
$243.17M |
$3.94
+0.13%
|
|
BioVascular Pancreas (BVP) is a cell-based therapy program (islet-related) in preclinical/early development, aligning with Biotech - Cell Therapy.
|
$241.99M |
$1.56
-4.29%
|
|
Directly develops autologous mRNA CAR-T cell therapy (Descartes-08) for autoimmune diseases.
|
$241.89M |
$9.32
-8.09%
|
|
Lifecore operates as a pure-play CDMO focused on sterile injectable manufacturing (contract manufacturing for pharma/biotech).
|
$240.66M |
$6.50
-2.40%
|
|
Lanifibranor is Inventiva's lead asset, an orally administered small molecule therapeutic in Phase 3 for MASH, representing the core product focus.
|
$238.77M |
$4.55
-6.19%
|
|
Silence's core business is RNAi therapeutics, anchored by its mRNAi GOLD GalNAc siRNA platform and wholly-owned programs.
|
$235.84M |
$5.00
-7.41%
|
|
Enanta is actively developing antiviral small-molecule therapeutics (RSV programs and related assets), aligning with the 'Antiviral Small-Molecule Therapeutics' theme.
|
$235.57M |
$11.02
-4.26%
|
|
Vor Biopharma's core focus is oncology therapies developed via engineered cell/gene therapies for blood cancers.
|
$234.05M |
$37.46
+1.57%
|
|
Company is a clinical-stage oncology biotech developing MasterKey targeted cancer therapies (BDTX-1535, BDTX-4933).
|
$232.57M |
$4.09
-6.41%
|
|
Core drug delivery platform enabling intracellular delivery of therapeutics across multiple programs.
|
$231.14M |
$6.09
-10.44%
|
|
Company is a clinical-stage biotechnology firm focused on oncology therapies (MICVO ADC).
|
$229.21M |
$3.70
-3.39%
|
|
Lonigutamab is a monoclonal antibody therapeutic developed by ACELYRIN for Thyroid Eye Disease.
|
$228.61M |
$2.27
|
|
Company focuses its proprietary siRNA therapies on rare diseases and orphan conditions (PV is rare) with high unmet needs.
|
$226.72M |
$1.60
|
|
Foghorn Therapeutics is a clinical-stage biotech focused on oncology therapies targeting the chromatin regulatory (epigenetic) system, aligning with Biotech - Oncology.
|
$226.31M |
$4.06
-8.76%
|
|
ESK-001 and A-005 are oral small-molecule TYK2 inhibitors, a core direct product category.
|
$224.15M |
$4.29
+4.25%
|
|
Atebimetinib is an oral small-molecule therapeutic being developed for oncology.
|
$220.59M |
$6.13
-2.23%
|
|
Directly develops AAV-based gene therapies for cardiovascular and neurodegenerative genetic diseases (LX2006/LX2020).
|
$219.76M |
$6.62
-1.05%
|
|
Utilizes a proprietary drug delivery platform to target therapeutics to brain tumors, bypassing the blood-brain barrier.
|
$219.38M |
$11.53
-1.11%
|
|
Accelerator Laboratory provides contract research, sample testing, and assay development services similar to CRO offerings.
|
$219.00M |
$5.64
-6.00%
|
|
Direct product platform: a polymer-based micro-sphere drug delivery platform enabling local, extended-release therapeutics (Diffusphere) used in EP-104IAR and EP-104GI.
|
$216.23M |
$6.07
-1.78%
|
|
Codexis is pivoting to RNAi therapeutics manufacturing using the ECO Synthesis platform, aiming to become a direct supplier of siRNA materials.
|
$214.57M |
$2.59
-7.50%
|
|
Directly developing oncology therapies via gene-edited cell therapies (CAR-T), i.e., Biotech - Oncology.
|
$213.91M |
$2.30
+5.50%
|
|
GNFT's core business is oral small-molecule therapeutics (elafibranor in PBC; additional drug candidates GNS561 and VS-01) across liver diseases.
|
$212.11M |
$4.25
-2.29%
|
|
Lead product Foralumab is a fully human monoclonal antibody, making Monoclonal Antibody Therapeutics a core directly produced asset.
|
$210.30M |
$2.04
-5.56%
|
Showing page 4 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
